Evolution of delayed resistance to immunotherapy in a melanoma responder

Evolution of delayed resistance to immunotherapy in a melanoma responder

Despite initial responses1-3, most melanoma patients develop resistance4 to immune checkpoint blockade (ICB). To understand the evolution of resistance, we studied 37 tumor samples over 9 years from a patient with metastatic melanoma with complete clinical response to ICB followed by delayed recurre...

Full description

Bibliographic Details
Main Author: Kellis, Manolis
Other Authors: Massachusetts Institute of Technology. Computer Science and Artificial Intelligence Laboratory
Format: Article
Language:English
Published: Springer Science and Business Media LLC 2022
Online Access:https://hdl.handle.net/1721.1/143713

Similar Items

Similar Items